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Continuing Education

Bipolar Disorder: A Pharmacotherapy Management Overview

by Huong Le, Pharm.D. Candidate 2014, Julie Nguyen, Pharm.D. Candidate 2014, Tina Pham, Pharm.D. Candidate 2014, Laura Tsu,
Pharm.D., BCPS, Midwestern University College of Pharmacy – Glendale
Goals
This home-study CPE activity has been
developed to educate pharmacists on
bipolar disorder and its management using
non-pharmacologic and pharmacologic
therapies.
Objectives
1. Distinguish between Bipolar Disorder
I and Bipolar Disorder II and the
different mood disorders
2. Compare the differences between a
manic and a depressive state
3. Develop a therapeutic plan for a
newly diagnosed bipolar patient
4. Compare different pharmacologic
agents in terms of efficacy, adverse
effects, and monitoring
5. Design treatment recommendations
for special population groups
Introduction
Bipolar disorder is a common and
debilitating mood disorder, with an
estimated lifetime prevalence of bipolar
I disorder and bipolar II disorder of 1%
and 1.1%, respectively, in the United
States.1 The mean age of onset for bipolar
I disorder and bipolar II disorder is 18 and
20 years, respectively, with equal gender
prevalence occurring in bipolar I disorder
and a higher prevalence in women for
bipolar II disorder.1 The pathophysiology
of bipolar disorder is unknown, but the
etiology is thought to involve biological,
psychological, and social factors. There
is a complex genetic component with
80-90% of patients with bipolar disorder
having a relative with a mood disorder.
The brain structure and function in these
patients are also altered, but it is unclear
if these changes occurred before or after
clinical presentation of the disorder.1
Environmental influences such as stressful
life events, alcohol or substance abuse,
and changes in sleep-wake cycle may
also affect the course of the disorder
by dysregulating neurotransmitters,
hormones, endocrine function,
neuropeptides, cations, intracellular
messengers, and signal transduction
pathways. Appropriately diagnosing
bipolar disorder is crucial, because there
are other psychiatric and neurologic
disorders that may present similarly with
manic-like or depressive-like symptoms.1

For example, if an individual with bipolar
disorder was misdiagnosed to have
attention-deficit/hyperactivity disorder
(ADHD), the central nervous system
stimulant prescribed can actually worsen
symptoms of mania or depression and
decrease response to treatment. There are
three types of bipolar disorder. Bipolar I
Disorder primarily presents with manic,
or rapid cycling episodes of mania and
depression. Bipolar II Disorder primarily
presents with recurrent depression
accompanied by hypomanic episodes.
Cyclothymic Disorder is a chronic state
of cycling between hypomanic and
dysthymic episodes that do not reach the
diagnostic criteria for bipolar disorder.1
Diagnosis
Major Depressive
Depressed mood and/or loss of interest or
pleasure for at least 2 weeks and at least 5
of the following:2
1. Depressed mood
2. Decreased interest or pleasure in
normal activities
3. Unintentional weight loss or gain
4. Insomnia or hypersomnia
5. Agitation or psychomotor retardation
6. Fatigue or decreased energy
7. Feelings of worthlessness or guilt
8. Decreased ability to concentrate or
make decisions
9. Suicidal thoughts
Dysthymic Disorder
Depressed mood for more days than not
for at least 2 years and at least 2 of the
following:2
1. Loss of appetite or overeating
2. Insomnia or hypersomnia
3. Fatigue or decreased energy
4. Low self-esteem
5. Decreased ability to concentrate or
make decisions
6. Feelings of hopelessness
Manic
Abnormal and persistent elevated mood
for at least 1 week and at least 3 of the
following:2
1. Inflated self-esteem or grandiosity
2. Decreased need for sleep
3. Increased talking
4. Flight of ideas or racing thoughts
5. Distractible
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6.
7.
8.

Increased activity (socially, at work,
or sexually)
Increased psychomotor agitation
Excessive involvement in pleasurable
activities that have high risk for
serious consequences

Hypomanic
Abnormal and persistent elevated mood
for at least 4 days and at least 3 of the
following:2
1. Inflated self-esteem or grandiosity
2. Decreased need for sleep
3. Increased talking
4. Increased activity (socially, at work,
or sexually)
5. Increased psychomotor agitation
6. Excessive involvement in pleasurable
activities that have high risk for
serious consequences
Mixed
Criteria for both major depressive and
manic episodes that occur almost every
day for at least a 1 week period.2
Rapid cycling
More than 4 major depressive or manic
episodes (manic, hypomanic, or mixed) in
12 months.2
Non-Pharmacological Treatments
The goals of treatment for bipolar
disorders aim to achieve remission,
which is defined as complete return
to normal functioning and lack of
symptoms, to prevent relapses, to control
comorbid conditions including anxiety,
panic disorder, obsessive-compulsive
disorder (OCD), and ADHD. Three
non-pharmacological approaches to the
treatment of bipolar disorders encompass
health maintenance, mood charting, and
a combination of pharmacotherapy plus
psychoeducation.3 Maintaining health
through adequate sleep, nutrition, and
exercise can improve and prevent signs
and symptoms of bipolar episodes.
Benzodiazepines, melatonin, enforced
darkness, and prolonged bed rest have
been shown to help patients sleep. Sleep
hygiene is also crucial in obtaining
adequate sleep. This includes counseling
patients to establish a fixed sleep and
wake time, to exercise but not close to
bedtime, and to avoid naps. In addition
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to getting adequate sleep, nutrition plays
an important role in managing bipolar
disorders. Patients should be counseled to
maintain an adequate intake of essential
amino acids, fatty acids, vitamins, and
minerals based on the Reference Daily
Intake (RDI).3 Exercise, either strength
training or aerobic, can help with sleep
and major depressive disorder (MDD) by
increasing the synthesis and release of
neurotransmitters such as serotonin and
norepinephrine.4 Mood charting is another
approach to manage bipolar disorders by
assisting patients in detecting signs and
symptoms of episodes and assessing their
responsiveness and tolerability to the
drug regimen. Finally, a combination of
pharmacotherapy and psychoeducation
can enhance the treatments and prevent
relapses of bipolar episodes. Cognitive
behavior therapy, reducing psychosocial
stressors, mental health organizations, and
other support groups, including individual
or family therapy, are recommended as
adjunct therapies to pharmacologic agents.
Other non-pharmacologic approaches
have been shown to be effective in
treating patients who have failed
pharmacologic agents. These approaches
include electroconvulsive therapy (ECT),
transcranial magnetic stimulation, and
vagus nerve stimulation.
Pharmacological Treatments
Manic Phase (Acute Manic, Hypomanic,
Mixed)
The manic phase can be acute manic,
hypomanic, or mixed. The treatment plans
in the manic phase include remission,
assessment of the causes and triggers
such as alcohol, drug, or substance
abuse. Other contributory factors can be
stimulants, caffeine, or antidepressant
monotherapy. For severe cases of mania,
first line treatments are combinations of
lithium plus antipsychotics or valproate
plus antipsychotics.5,6 For less severe
cases, lithium, valproate, or antipsychotic
monotherapy is sufficient. Alternatives to
lithium or valproate can be carbamazepine
or oxcarbazepine. Adjunctive therapy
with psychosocial approaches can also be
beneficial. For mixed or rapid cycling,
valproate is preferred over lithium.
Whenever psychosis is manifested in
the manic phase, antipsychotics need
to be considered.5,6 Second generation
antipsychotics (SGAs), also known as
atypical antipsychotics are preferred
over first generation antipsychotics

(FGAs), also known as typical
antipsychotics. SGAs have lower risk of
extrapyramidal side effects such as tardive
dyskinesia, dystonia, and Parkinson’s
like symptoms and have less effects
on prolactin.5,6 Examples of SGAs are
olanzapine, ziprasidone, risperidone,
and quetiapine. Examples of FGAs
are chlorpromazine, fluphenazine, and
haloperidol. For breakthrough manic
or mixed episodes, the dose should be
optimized to the therapeutic range, add
or continue antipsychotics, or consider
adding a short-term benzodiazepine. If
patients are refractory to the first line
treatments, the recommendations are to
add another first line agent, carbamazepine
or oxcarbazepine, add or switch an
antipsychotic, or utilize ECT.5,6
Depressive Phase
The treatment plans for the depressive
phase aim to achieve remission, avoid
antidepressant monotherapy due to
precipitation of mania or hypomania,
assess causes or triggers of depression
such as alcohol, drug or substance
abuse, and to taper off antipsychotics,
benzodiazepines, and sedative-hypnotics.
First line agents for bipolar depression
are lithium or lamotrigine. Alternative
agents are quetiapine monotherapy or
olanzapine plus fluoxetine, valproate,
lithium plus antidepressant, or adjunctive
psychotherapy.5,6 In July 2013, lurasidone
was approved as monotherapy or
adjunctive therapy in the treatment of
bipolar depression. For breakthrough
bipolar depression, optimize dose of
the maintenance drug until it is within
therapeutic range.7 For patients who are
refractory to first line treatments, add
lamotrigine, bupropion, paroxetine or
alternatively add other antidepressants or
monoamine oxidase inhibitors (MAOIs).
ECT is recommended for severe,
refractory depression with psychosis or
catatonia.5,6
Rapid Cycling
The treatment plans for rapid cycling
are to reduce the numbers of episode
and assess issues that can contribute to
cycling, including hypothyroidism, drug or
substance abuse, or alcoholism. First line
agents include lithium or valproate, and an
alternative would be lamotrigine. Rapidcycling patients will eventually require
combination therapy.5,6

Maintenance Treatments
Following an episode, all patients
are required to be on maintenance
or continuation of therapy for up to
six months due to the high risk of
relapse. The selection of medications
for maintenance agents is the agent
that induces remission. Furthermore,
psychosocial therapies such as evaluating
adherence, support groups, lifestyle,
and mood charting are also considered.
First line agents for maintenance are
lithium or valproate with lamotrigine,
carbamazepine, or oxcarbazepine as
alternatives. Antipsychotics should be
evaluated for risks versus benefits before
considering them for long-term use. In
bipolar I, the duration of maintenance
after one manic episode is 12 months, and
lifelong for more than one episode. In
bipolar II, the duration of maintenance
after one to two hypomanic phases is 12
months, and lifelong if more than two
episodes.5,6
Drug Therapies
Lithium (Eskalith®, Lithobid®)
Lithium works by affecting the reuptake
of serotonin and norepinephrine. In
doing so, lithium can be used for the
depressive stage of bipolar. However,
lithium has a stronger effect on managing
mania by suppressing excitatory
neurotransmission (e.g. dopamine and
glutamate) while increasing inhibitory
activity (GABA).7 Studies have shown
that lithium has similar efficacy to
valproate, carbamazepine, risperidone,
olanzapine, chlorpromazine and other first
generation antipsychotics. Its efficacy is
enhanced in patients who have fewer prior
episodes, family history of responsiveness
to lithium, and euthymia between
episodes. In mixed or rapid-cycling, the
efficacy of lithium is reduced. Lithium
is used as a first line agent for mania,
hypomania, depression, and maintenance.
Combination therapy with carbamazepine,
valproate, and antipsychotics can be seen.
Adverse effects are seen in multiple
organs and can be dose dependent.
Central nervous system (CNS) effects
of headache, memory and cognitive
impairments, coma, confusion, seizure,
sedation, lethargy and stupor are dose
related. Other dose related side effects
include nausea, vomiting, diarrhea,
dyspepsia, weight gain, hair loss,
worsening of rash or psoriasis, and
tremor. Lithium can decrease response
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to antidiuretic hormones (ADH), causing
polyuria, polydipsia, and nocturia. Other
dose related effects on the kidneys include
albuminuria and glycosuria. Lithium
can accumulate in the thyroid gland
and interfere with synthesis of thyroid
hormones, thus causing hypothyroidism.
Lithium can also cause cardiac problems
such as atrioventricular (AV) block,
arrhythmias, hypotension, syncope and
ECG changes. Thus, patients with a
history of cardiac abnormalities need to
have their ECG monitored at baseline and
during treatment. Lithium can further lead
to leukocytosis and blurred vision. Unlike
other pharmacologic treatments for bipolar
disorder, the long term use of lithium can
reduce risk of suicidal ideation.
Drugs that can increase lithium
concentration include ACE inhibitors,
NSAIDs, and thiazides while theophylline,
caffeine, and loop diuretics can decrease
lithium concentration. Dehydration,
vomiting, or diarrhea can also raise
lithium levels. At the initiation of therapy,
serum levels are drawn twice weekly until
the level is stabilized. Once stabilized,
it is then recommended to draw levels
every 2 months. Serum concentrations
for acute episodes are 1 – 1.2 mEq/L
and 0.6 – 1.2 mEq/L for maintenance.
Furthermore, electrolytes, thyroid function
tests, hematologic and dermatologic
tests should be monitored at baseline and
every 6-12 months, with the exception of
dermatologic test, which should be done
every 3-6 months.
Monitoring serum levels of lithium is
important to avoid toxicity, which can be
seen when the serum level is greater than
1.5 mEq/L, with signs and symptoms of
tremor, nausea, diarrhea, blurred vision,
vertigo, and confusion. When the level
is greater than 2.5 mEq/L, toxicity is
manifested in seizures, dysrryhthmias,
and coma. Treatments for lithium toxicity
include gastric lavage, induction of
emesis, and hemodialysis when serum
concentration is above 2.5 mEq/L. For
dosing information, refer to Table 1.8,9

mood in mania. Studies have shown that
valproate has better efficacy than lithium
in patients with mixed episodes, many
prior mood episodes, and rapid cycling.
Similar efficacy is seen with olanzapine
and haloperidol. Valproate is used as first
line therapy for acute mania, hypomania,
mixed, and maintenance. It can also be
combined with lithium, carbamazepine,
and antipsychotics. After two weeks of
initiating therapy, trough levels of acute
manic or mixed episodes should be at 50 –
125 mcg/mL.
Adverse effects of valproate target
multiple organs and can be dose
dependent. The most common adverse
effects are dose-related nausea, vomiting,
diarrhea, abdominal pain, dyspepsia, and
flatulence. Valproate can also cause CNS
issues, including headache, somnolence,
dizziness, nervousness, and sedation.
Caution must be taken in patients with
liver disease because valproate can
increase liver function test (LFTs) and
precipitate hepatic failure. Valproate can
further cause tremor, weakness, diplopia,
and blurred vision. Rare but serious side
effects are hepatic failure, pancreatitis,
and agranulocytosis. Valproate is
contraindicated in pregnancy, with a black
box warning for teratogenicity, pregnancy
category X.
When combined with lamotrigine,
valproate will inhibit lamotrigine’s
metabolism and dosing adjustment is
therefore required. Valproate is highly
protein bound and will displace other
drugs readily. Finally, it will inhibit
CYP 450 isoenzymes 3A4, 2C9, and
2D6. Hematologic, hepatic, dermatologic
and metabolic tests should be monitored
at baseline, then every 3-6 months.
Serum levels should also be monitored
for toxicity, where sign and symptoms
include somnolence, heart block, and
coma. Treatment of toxicity would be
hemodialysis. Behavior changes and
suicide ideation should also be assessed
periodically. For dosing information, refer
to Table 1.8,9

Valproate (Depakote®)
Formulations of valproate consists
of valproate sodium, valproic acid, and
divalproex sodium. Valporate increases
the availability of gamma-aminobutyric
acid (GABA) and enhances or mimics
the action of GABA. By increasing
GABA activity, valproates can manage
the abnormal, persistent, and elevated

Carbamazepine (Tegretol®)
The mechanism of action of
carbamazepine is to decrease synaptic
transmission, decrease activity in the
thalamus, and decrease the transport
of sodium across cell membranes,
and potentiating GABA receptors.
By decreasing synaptic transmission
via blockage of sodium across cell
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membranes, cells are less excitable and an
abnormally elevated mood can be better
managed. Studies show that the efficacy
of carbamazepine is similar to lithium,
but less than valproate. Carbamazepine
is used as an alternative treatment and
be combined with lithium, valproate, or
antipsychotics. There is no established
goal serum level for carbamazepine in the
treatment of bipolar disorder. However,
the target serum level of 4 – 12 mcg/
mL for seizures is often used for bipolar
disorder.
The adverse effects of carbamazepine
include multiple organs, with the most
common side effects being CNS related:
dizziness, drowsiness, headache, ataxia,
cognitive and memory impairments,
and rare cases of neuroleptic malignant
syndrome (NMS). Cardiac issues caused
by carbamazepine include hypertension
or hypotension, syncope, AV block,
arrhythmias, and edema. Gastrointestinal
side effects are nausea, vomiting,
diarrhea, dry mouth/throat, and anorexia.
Impotence and polyuria can occur along
with increase in LFTs. Hematologic side
effects are agranulocytosis, anemia, and
thrombocytopenia. Carbamazepine can
induce symptoms of inappropriate ADH
(SIADH), abnormal thyroid function
test, hypocalcemia, and hyponatremia.
Certain populations, such as Asian, Native
American, Latin American, AfricanAmerican, and Indian are at greater
risks of developing Stevens-Johnson
syndrome (SJS) due to the presence of the
HLA-B*1502 allele.
In addition to being a CYP 3A4
inhibitor, carbamazepine also has a unique
mechanism of being able to autoinduce
its own metabolism. Thus, it is important
to adjust the dose based on patient’s
liver function. Since carbamazepine
can decrease the concentration of oral
contraceptives (OC), back up methods
or an increase in OC dose should be
considered. When combined with
clozapine, there is an increased risk of
bone marrow suppression. And when
added to valproate, the concentration of
carbamazepine will increase. Monitor
serum level for toxicity, which can be
manifested in dizziness, sedation, visual
changes, respiratory dysfunction, and
arrhythmias. Treatments of toxicity
include relieving symptoms, gastric
lavage, or hemoperfusion. For dosing
information, refer to Table 1.8,9

Oxcarbazepine (Trileptal®)
The mechanism of action of
oxcarbazepine is to decrease synaptic
transmission by blocking sodium voltagegated channels, similar to carbamazepine.
Studies have shown that oxcarbazepine
has similar efficacy to lithium and
haloperidol; however, these studies lack
power. Oxcarbazepine is used as an
alternative treatment for bipolar either
as monotherapy or in combination with
other agents, after patients have failed
carbamazepine, lithium, and valproate.
The advantages of oxcarbazepine over
carbamazepine include having fewer
adverse effects, fewer drug interactions,
and no autoinduction. However,
oxcarbazepine causes greater risk of
hyponatremia, which can cause nausea,
vomiting, confusion, and seizures.
The most common adverse effects
are CNS related, including dizziness,
drowsiness, headache, ataxia, vertigo,
fatigue, sedation. Other side effects are
nausea, vomiting, abdominal pain, along
with abnormal gait and tremor, diplopia
and nystagmus. Cross-sensitivity to
oxcarbazepine is seen in approximately
25% -30% of patients who are allergic
to carbamazepine. Hypersensitivity
reactions include angioedema and SJS.
Oxcarbazepine is a CYP 3A4 inducer and
CYP 2C19 inhibitor and will decrease
concentrations of oral contraceptives and
dihydropyridine calcium channel blockers.
It is recommended to monitor serum
levels of sodium for signs and symptoms
of hyponatremia while patients are on
oxcarbazepine. For dosing information,
refer to Table 1.8,9
Lamotrigine (Lamictal®)
Lamotrigine, a mood stabilizer, is
commonly used as a first-line treatment
for patients with bipolar II disorder.
There is a black box warning for
serious skin rashes, which may lead
to the SJS. The concomitant use with
valproate can increase this risk of rash.
Signs of rashes should be monitored
at baseline and every 3-6 months.
Common adverse effects include nausea,
vomiting, insomnia, ataxia, dizziness,
and headache. Carbamazepine increases
the metabolism of lamotrigine which
may result in subtherapeutic levels of
lamotrigine. There are also drug-drug
interactions with oral contraceptives.
The estrogen component can decrease
the effectiveness of lamotrigine, while
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lamotrigine can decrease the effectiveness
benzodiazepines. Benzodiazepines may
of oral progestin contraceptives. Doses
also increase the serum level of selective
should be decreased in renal and hepatic
serotonin reuptake inhibitors (SSRIs),
impairment. LFTs and serum creatinine
which increases the risk of psychomotor
(SCr) should be monitored regularly
impairments. For dosing information,
during therapy. Anticonvulsants increase
refer to Table 1.8,9
the risk of suicidal thoughts and behaviors,
so patients should be monitored for
Selective Serotonin Reuptake Inhibitors
emergence or worsening of depression or
Examples of SSRIs are citalopram
suicidal ideation. For dosing information,
(Celexa®), escitalopram (Lexapro®),
refer to Table 1.8,9
fluoxetine (Prozac®), paroxetine (Paxil®),
and sertraline (Zoloft®). SSRIs are
®
Quetiapine (Seroquel )
generally used as first line antidepressants
Quetiapine, an atypical antipsychotic,
because of their safety in overdose
is used for the acute treatment of
and improved tolerability. Common
manic episodes associated with bipolar
adverse effects include nausea, vomiting,
disorder, acute treatment of depressive
diarrhea, headache, insomnia, and sexual
episodes associated with bipolar I and
dysfunction. Citalopram can also cause
II, and maintenance treatment of bipolar
dose-related QT prolongation and doses
I disorder. Common adverse effects
should not exceed 40 mg/day for all
include increase in diastolic and systolic
patients and should not exceed 20 mg/day
blood pressure in children, somnolence,
for patients over 60 years old, have hepatic
headache, agitation, dizziness, metabolic
impairment, or are concurrently taking
effects, dry mouth, weight gain, and
a CYP 2C19 Inhibitor (e.g. omeprazole,
increased appetite. Concomitant use with
cimetidine). Abrupt withdrawal can cause
acetylcholinesterase inhibitors should
flu-like symptoms, light-headedness or
be avoided since severe extrapyramidal
dizziness, uneasiness, sleep disturbances,
and headache. Therefore, SSRIs should
symptoms may be precipitated. CYP3A4
inducers (e.g. progesterone, phenytoin,
be tapered down when discontinuing
oxcarbazepine, carbamazepine, and
treatment with the exception of fluoxetine
phenobarbital) may decrease the
due to its long half-life. SSRIs are highly
serum level of quetiapine. To maintain
bound to plasma protein and co-admission
with other highly protein-bound drugs
therapeutic benefit, quetiapine doses may
be increased to up to 5 times when used
(e.g. valproate, warfarin, digoxin) may
with CYP3A4 inducers. Fasting lipid
cause changes in serum concentrations
profile (FLPs) should be monitored due
of either drugs. SSRIs have varying
to metabolic increases in triglyceride and
degrees of CYP 2D6 inhibition and
decreased HDL levels. Weight, blood
may affect drugs that are metabolized
pressure, worsening of depression or
by this isoenzyme (e.g. phenothiazine
suicidal ideation should be monitored
antipsychotics, risperidone). Fluoxetine
regularly. For dosing information, refer to and paroxetine are strong CYP 2D6
Table 1.8,9
inhibitors while sertraline is a moderate
CYP 2D6 inhibitor, and citalopram
Benzodiazepines
and escitalopram are weak CYP 2D6
The most commonly studied and used
inhibitors. Citalopram and escitalopram
benzodiazepines in bipolar disorder are
are metabolized by CYP 3A4 and CYP
lorazepam (Ativan®) and clonazepam
2C19, and concomitant use with a CYP
(Klonopin®), which has beneficial effects
3A4 inducer (e.g. carbamazepine) may
in the treatment of hypomanic, mild to
decrease their serum levels. Use of a
moderate manic, and mixed episodes.5
SSRI with a MAOI is contraindicated
Benzodiazepines are generally used as
due to the increased risk of hypertensive
adjunctive therapy for treating insomnia,
crisis, serotonin syndrome, and delirium.
agitation, and anxiety in bipolar patients
There is a Black Box Warning of increased
with elevated moods. Common adverse
suicidal ideation with antidepressant use
effects include sedation, respiratory
and suicidal thoughts should be assessed
depression, hypotension, and changes in
and monitored regularly. For dosing
appetite, and therefore respiratory and
information, refer to Table 1.8,9
cardiovascular status should be closely
monitored. Concomitant use with
Bupropion (Wellbutrin®)
olanzapine may increase the toxicity of
Bupropion works as an antidepressant
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by inhibiting norepinephrine and
dopamine reuptake. Common adverse
effects include nausea, vomiting, dry
mouth, skin reactions, insomnia, and
seizures. Bupropion is metabolized
by CYP 2B6 and has few drug-drug
interactions. However, concomitant
use with carbamazepine may lower
bupropion levels and dose adjustments
may be required. Contraindications with
bupropion include concomitant use with
a MAOI, seizure disorder, and history of
an eating disorder. There is a Black Box
Warning of increased suicidal ideation
with antidepressant use and suicidal
thoughts should be assessed and monitored
regularly. For dosing information, refer to
Table 1.8,9

antidepressants. Overdose can occur
and symptoms may include irritability,
hyperactivity, anxiety, tachycardia,
drowsiness, and hallucinations. There
are many drug-drug interactions
and contraindications to MAOIs
include concomitant use with other
antidepressants, pheochromocytoma,
congestive heart failure, hepatic
impairment, renal impairment,
cerebrovascular disorders, cardiovascular
disease, hypertension, and history of
headache. There is a Black Box Warning
of increased suicidal ideation with
antidepressant use and suicidal thoughts
should be assessed and monitored
regularly. For dosing information, refer to
Table 1.8,9

Venlafaxine (Effexor®)
Venlafaxine is a serotonin and
norepinephrine reuptake inhibitor (SNRI)
that is generally used as a second-line
antidepressant. Common adverse effects
include significant nausea, constipation,
dry mouth, decreased appetite, headache,
somnolence, dizziness, insomnia,
dose-related increase in diastolic blood
pressure, and sexual dysfunction. Blood
pressure should be monitored regularly,
and doses should be decreased in patients
with renal and/or hepatic impairment.
Abrupt withdrawal with SNRIs may be
worse than with SSRIs and symptoms
may include agitation, confusion,
excessive sweating, hallucinations, and
hyperreflexia. There are minimal drugdrug interactions but concomitant use
with a MAOI is contraindicated. There
is a Black Box Warning of increased
suicidal ideation with antidepressant use
and suicidal thoughts should be assessed
and monitored regularly. For dosing
information, refer to Table 1.8,9

Olanzapine/ fluoxetine (Symbyax®)
This combination agent contains
olanzapine, a SGA that inhibits
serotonin, dopamine, histamine, and
alpha1-adrenergic reuptake, and the
SSRI fluoxetine. Due to the synergistic
increase in serotonin, norepinephrine,
and dopamine, there is an enhanced
antidepressant effect for this drug
combination. Olanzapine/fluoxetine is
commonly used for depressive episodes
associated with bipolar I disorder and
treatment-resistant depression, which
is defined as being unresponsive to two
trials of different antidepressants in
the current episode. Common adverse
reactions to this combination agent include
somnolence, fatigue, hyperprolactinemia,
weight gain, increased appetite, and
dry mouth. There are many drug-drug
interactions associated with olanzapine/
fluoxetine and concomitant use with
other SSRIs, antipsychotics, and lithium
may lead to serotonin syndrome/toxicity.
Concomitant use with a MAOI should be
avoided. Doses should be decreased in
hepatic impaired and hypotensive patients,
and LFTs and blood pressure should be
monitored regularly in these patients. For
dosing information, refer to Table 1.8,9

Monoamine Oxidase Inhibitors
MAOIs such as selegiline (Emsam®),
phenelzine (Nardil®), and tranylcypromine
(Parnate®) work by increasing
concentrations of norepinephrine,
serotonin, and dopamine. They are rarely
used as a first line drug therapy and
are indicated for patients with atypical
depression or patients unresponsive to
other antidepressants. Common adverse
effects include orthostatic hypertension,
sedation, stimulant, weight gain, and
sexual dysfunction. Hypertensive
crisis may occur when taken with
food containing tyramine and other

Special Populations
Women and Pregnancy
Due to higher risks of birth
malformations associated with
medications used to treat bipolar
disorder, all female patients of
childbearing age are encouraged to
practice effective contraceptive methods
while on pharmacological therapy.5
Oral contraceptives should be avoided
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in patients taking carbamazepine,
oxcarbazepine, and topiramate because
these medications increase the metabolism
of oral contraceptives, thus decreasing
their effectiveness. Effective backup
contraceptive practices, such as condoms
or intrauterine devices, are recommended
for birth control in these patients.
When a patient is pregnant, the risks and
benefits of continuing versus discontinuing
medications for bipolar disorder should be
evaluated carefully. Should the decision
be made to continue pharmacotherapy,
clinicians and pharmacists should choose
drugs with fewer known teratogenic
effects and when possible, the lowest
effective dose should be used. Congenital
malformations have been documented
with first-trimester exposure to lithium,
valproate, and carbamazepine. A common
neonatal complication associated with
lithium use near labor is the “floppy
baby” syndrome, which is characterized
by cyanosis and hypotonicity. The use
of carbamazepine and valproate sodium
during the first trimester has been
associated with neural tube defects.10
Benign risks have been documented
with SSRIs use during pregnancy, with
fluoxetine and citalopram having the
strongest safety data. Similarly, past
studies have demonstrated no association
between lorazepam and clonazepam with
birth defects. However, diazepam remains
controversial due to earlier reports of
increased risks of oral cleft malformations
during the first trimester.10 Antipsychotic
medications may be added to the bipolar
regimen to treat psychotic features. Highpotency antipsychotic agents are preferred
due to their decreased anticholinergic,
antihistaminergic, and hypotensive
effects.5 Use of high-potency agents
near term, however, has demonstrated
short-lived extrapyramidal side effects in
neonates. Haloperidol is recommended
as the first line therapy because it is not
associated with congenital anomalies.5
Prenatal monitoring is recommended
for all females who choose to remain
on lithium, valproate, or carbamazepine
during their pregnancy.12 At the
20th week of gestation, a maternal
serum of α-fetoprotein screening for
neural tube defects is recommended
with amniocentesis. Ultrasound
examination at 16-18 weeks gestation
is also recommended to detect cardiac
abnormalities. Close monitoring of the
serum drug levels should be continued

Continuing Education (continued from page 40)
throughout the pregnancy due to changes
in hepatic metabolism, renal excretion,
and fluid volumes.

It is crucial that the patients and
their family members understand the
importance of medication adherence
for safety and efficacy purposes. For
instance, patients may not be aware that
abrupt discontinuation of an SSRI may
lead to withdrawal syndromes or that
non-adherence can worsen their mood
episodes. It is especially essential to
educate special patient populations, such
as patients with pregnancy and lactation
concerns due to the high teratogenic risk.
It is also important to educate the patients
and their family members to identify
behavioral changes and early signs of
suicidal ideation as serious side effects of
the medication. Overall, pharmacists can
have a significant role in the management
and well-being of their bipolar patients
by helping them to monitor and provide
education about their disease state.
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Postpartum and Breast-feeding
During the postpartum period, females
are more likely to relapse into mania,
depression, or psychosis. Women with
previous postpartum episodes have the
highest risk to have another affective
episode after subsequent pregnancies.
Therefore, prophylactic medications such
as lithium or valproate are recommended
in women with bipolar disorder to prevent
postpartum mood episodes.5 Pharmacists
should also counsel women on the
importance of maintaining a normal sleep
pattern to avoid precipitating episodes of
mania.
Although all medications used in the
treatment of bipolar disorder are secreted
in breast milk at different degrees, the
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benzodiazepines are found in measurable
levels in breast milk and have the potential
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Drug Dosing
1
to affect the infant’s central nervous
system.
Drug

Pharmacist Role/Conclusion
Bipolar disorder can be effectively
managed with the help of pharmacists,
physicians, and psychiatrists. As clinical
pharmacists, obtaining an accurate and
complete medication history is critical to
identifying potential medication-related
causes of mood episodes. Pharmacists can
also help to assess the number of manic
and depressive episodes throughout the
course of therapy to optimize the patient’s
medication therapy. Patient education
is an important component to successful
therapy management. By educating the
patient about the disease state and the
drug therapy, patients are empowered
to take charge of their own health and
are therefore more likely to maintain
medication adherence. In addition,
performing long-term monitoring as part
of medication therapy management can
increase patient adherence and reduce
future hospitalizations.

Lithium

ACPE UAN#0100-0000-14-018-H01-P

Initial Dose (mg/day)
900 in 3-4 divided doses

Usual Dose (mg/day)

Valproate

750 in 3 divided doses

0.5-1.2 mEq/L (serum
level)
60 mg/kg

Carbamazepine

400 in 2 divided doses

800-1000

Oxcarbazepine

600

1200

Lamotrigine

25-50

100-400

Olanzapine/Fluoxetine

6/25

6-12(O)/25-50(F)

Quetiapine

50

300-800

Citalopram

20

20-40

Escitalopram

10

10-20

Fluoxetine

20

20-60

Paroxetine

20

20-60

Sertraline

50

50-200

Buproprion

150

150-300

Venlafaxine

37.5-75

75-375

Selegiline

6

6-12

Phenelzine

45 in 3 divided doses

45-90

10

30-60

Tranylcypromine
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